References
- Dobosz P , DzieciatkowskiT. The intriguing history of cancer immunotherapy. Front. Immunol.10, 2965 (2019).
- Mansh M . Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J. Biol. Med.84(4), 381–389 (2011).
- Waldman AD , FritzJM, LenardoMJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol.20(11), 651–668 (2020).
- Upadhaya S , Hubbard-LuceyVM, YuJX. Immuno-oncology drug development forges on despite COVID-19. Nat. Rev. Drug Discov.19(11), 751–752 (2020).
- Hassanein M , PartridgeMA, ShaoW, TorriA. Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?Bioanalysis12(18), 1325–1336 (2020).
- Oldenburg J , SchroderJ, BrackmannHH, Muller-ReibleC, SchwaabR, TuddenhamE. Environmental and genetic factors influencing inhibitor development. Semin. Hematol.41(1 Suppl. 1), 82–88 (2004).
- Shankar G , PendleyC, SteinKE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol.25(5), 555–561 (2007).
- Agency EM. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use (2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf
- van Brummelen EM , RosW, WolbinkG, BeijnenJH, SchellensJH. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist21(10), 1260–128 (2016).
- Davda J , DeclerckP, Hu-LieskovanSet al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J. Immunother. Cancer7(1), 105 (2019).
- Desnoyer A , BroutinS, DelahousseJet al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur. J. Cancer128, 119–128 (2020).
- Parcesepe P , GiordanoG, LaudannaC, FebbraroA, PancioneM. Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer. Gastroenterol. Res. Pract.2016, 6261721 (2016).
- Chida K , NakanishiK, ShomuraHet al. Spontaneous regression of transverse colon cancer: a case report. Surg. Case Rep.3(1), 65 (2017).
- Booth B , StevensonL, PillutlaRet al. 2019 White Paper on recent issues in bioanalysis: FDA BMV guidance, ICH M10 BMV guideline and regulatory inputs (part 2 – recommendations on 2018 FDA BMV guidance, 2019 ICH M10 BMV draft guideline and regulatory agencies' input on bioanalysis, biomarkers and immunogenicity). Bioanalysis11(23), 2099–2132 (2019).
- Stevenson L , RichardsS, PillutlaRet al. 2018 White Paper on recent issues in bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (part 3 – LBA/cell-based assays: immunogenicity, biomarkers and PK assays). Bioanalysis1(24), 1973–2001 (2018).
- Gupta S , RichardsS, AmaravadiLet al. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (part 3 – LBA: immunogenicity, biomarkers and PK assays). Bioanalysis9(24), 1967–1996 (2017).
- Shankar G , ArkinS, CoceaLet al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J.16(4), 658–673 (2014).
- US Department of Health and Human Services UF, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Immunogenicity testing of therapeutic protein products – developing and validating assays for anti-drug antibody detection. Guidance for industry. (2019).
- Wells AF , ParrinoJ, ManganEKet al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol. Ther.6(3), 339–352 (2019).
- Eli M , RothAG, AlbericoCatapanoet al. Impact of anti-drug antibodies to alirocumab on ldl-c lowering efficacy and safety. JACC67(13), (2016).